Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Moodys
Dow
Johnson and Johnson
Mallinckrodt

Last Updated: October 23, 2019

DrugPatentWatch Database Preview

ZEVALIN Drug Profile

See Plans and Pricing

« Back to Dashboard

Summary for Tradename: ZEVALIN
Recent Litigation for ZEVALIN

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Biogen Idec, Inc. v. Glaxosmithkline LLC2010-03-24
IDERA PHARMACEUTICALS, INC. v. KAPPOS2010-01-29
Genentech, Inc. v. Sanofi-Aventis Deutschland GMBH2008-10-27

See all ZEVALIN litigation

US Patents for ZEVALIN

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial Bayer Intellectual Property GMBH (Monheim, DE) 2026-12-05 RX Orphan search
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial LegoChem Biosciences, Inc. (Daejeon, KR) 2034-05-28 RX Orphan search
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Start Trial The Regents of the University of California (Oakland, CA) 2033-03-14 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Supplementary Protection Certificates for ZEVALIN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
122015000061 Germany   Start Trial PRODUCT NAME: TRASTUZUMAB UND RECOMBINANTE HUMANE HYALURONIDASE; REGISTRATION NO/DATE: EU/1/00/145/002 20130826
16/2004 Austria   Start Trial PRODUCT NAME: IBRITUMOMAB TIUXETAN; REGISTRATION NO/DATE: EU/1/03/264/001 20040116
C300156 Netherlands   Start Trial PRODUCT NAME: IBRITUMOMAB; REGISTRATION NO/DATE: EU/1/03/264/001 20040116
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
McKesson
Moodys
AstraZeneca
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.